Teva Sets November R&D Day to Outline Pipeline and Growth Strategy
Teva Pharmaceutical Industries will host an R&D Day in New York City on November 11, 2026. Leadership plans to discuss the company's research pipeline, potential value creation over the next five years, and its Pivot to Growth strategy. The event will run from 8:30 a.m. to 12:30 p.m. Eastern Time, with a live webcast available and in-person attendance by invitation only.
Teva Pharmaceutical Industries will hold an R&D Day in New York City on Nov. 11, 2026. Management plans to discuss its research pipeline, potential five-year value creation, and the Pivot to Growth strategy. The event runs from 8:30 a.m. to 12:30 p.m. Eastern Time.
In-person attendance is invitation-only because space is limited; invited analysts and institutional investors will receive separate registration instructions. A live webcast and presentation materials will be available on Teva's investor relations website, with an archived webcast expected within 24 hours. Teva says it is shifting toward innovative biopharma while retaining a large generics operation, with activities in neuroscience, immunology, complex generics, biosimilars, and pharmacy brands.
The R&D Day could shape how investors, clinicians, and patients view Teva's direction. If the pipeline and Pivot to Growth strategy deliver, patients in neuroscience and immunology may gain new treatment options, while generic and biosimilar users could benefit from broader access. If progress disappoints, investment and confidence may weaken. The event itself is unlikely to change medicine immediately; its main societal effect may come through future research priorities, partnerships, and the availability of affordable alternatives.